Form 4: Jerrold Grossman Acquires ADMA Biologics Shares

Jerrold Grossman, a Director at ADMA Biologics, Inc., reported the acquisition of 12,500 shares of common stock on May 12, 2026.

Summary

• Director Jerrold B. Grossman acquired 12,500 shares of ADMA Biologics, Inc. common stock through an open market purchase on May 12, 2026, at a price of $8.01 per share.
• Following this transaction, Mr. Grossman beneficially owns a total of 513,884 shares of common stock.
• This total includes shares held directly, indirectly through various entities (Brookwood LLC, Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc.), and shares held by his wife.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the direct stock purchase by a company director, indicating insider confidence.

Positives

• Director Jerrold B. Grossman made a significant open market purchase of 12,500 shares, indicating personal investment and confidence in the company.
• The acquisition of 12,500 shares at $8.01 per share demonstrates a direct financial commitment by a key insider.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider purchases, such as this one by Director Jerrold B. Grossman, can often be interpreted as a positive signal by the market, suggesting a belief in the company's future prospects.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal of management's confidence in the company's future performance.

Key Dates

Recommendation

The filing reports a routine insider purchase by a director, which is generally a positive indicator but does not provide sufficient new strategic or financial information to warrant a strong buy or sell recommendation. It suggests confidence but doesn't fundamentally alter the investment thesis without further context.

Keywords

ADMA Biologics, Form 4, Insider Trading, Stock Acquisition, Director, Beneficial Ownership, Common Stock, SEC Filing